We identified that the up-regulation of three miRNAs (hsa-miR-146a, hsa-miR-148a and hsa-miR-545), which target BRCA1/2, in patients with wild-type BRCA1/2 was associated with good overall survival (OS) and progression-free survival (PFS), a finding that has important implications for the clinical management of ovarian cancers. The gene discussed is BRCA1; the disease is ovarian cancer.